MERIDIANBristol Myers Squibb
Live view: Yahoo
Identity (GLEIF Global LEI Index)
| Field | Value | Class |
|---|---|---|
| Legal name | Bristol Myers Squibb | SF |
| LEI | Unavailable | SF |
| Swiss UID | Not in GLEIF record | SF |
| Jurisdiction | Unavailable | SF |
| Legal address | Unavailable | SF |
| Headquarters | New York City, New York | SF |
| Entity status | Unavailable | SF |
| Geneva connection | unresolved | CM |
Listed securities (SIX Swiss Exchange issuer directory)
| ISIN | Ticker | MIC | Share class | Segment | Accounting standard | Next GM | Auditor | Prov. |
|---|---|---|---|---|---|---|---|---|
| BMY | Pharmaceuticals | — | not announced | — | ⓘ |
Market snapshot
60.74 USD
Stale — 10 days old · delayed per exchange agreement · yahoo
| Metric | Value | Class |
|---|---|---|
| SMA 20 | 57.34 | CM |
| SMA 50 | 56.96 | CM |
| 52-week range position | 92% of range 42.60–62.37 | CM |
| Trend (SMA20 vs SMA50) | sideways | CM |
| History depth | 261 daily bars | SF |
Analyst price targets
| Low | Mean | Median | High | Analysts | Provider | As of |
|---|---|---|---|---|---|---|
| 40.0 | 62.95833 | 63.0 | 75.0 | 24 | yahoo_analyst | 2026-07-18T22:54:39Z |
Consensus recommendation (provider-published): buy
Financials (latest reported period)
Most recent reported income-statement figures (company disclosure redistributed by the named source); absent figures stay absent — never estimated.
Period ending 2025-12-31 (annual) · reported in USD
| Metric | Value | Class |
|---|---|---|
| Revenue | 48.2B USD | CD |
| Gross profit | not disclosed | CD |
| Operating income | not disclosed | CD |
| EBITDA | not disclosed | CD |
| Net income | 7.1B USD | CD |
| EPS | 3.46 | CD |
Recent company events
News, insider transactions, congressional trading disclosures and analyst-estimate snapshots from connected sources, each with provenance. Analyst estimates are forecasts — never price targets.
Segment & geographic revenue (company disclosures)
Figures parsed from filings and redistributed by the named provider; values are shown as reported and shares are Calculated Metrics with the formula in the column header.
Geographic split — period ending 2025-12-31
| Disclosed label | Value (as reported in the filing — no currency asserted) | Share of disclosed total (CM: value ÷ axis total) | Class | Prov. |
|---|---|---|---|---|
| United States | 99,837,000,000 | 69.1% CM | CD | ⓘ |
| International | 41,484,000,000 | 28.7% CM | CD | ⓘ |
| Other | 3,261,000,000 | 2.3% CM | CD | ⓘ |
How the company makes money
Business description and sector are sourced facts (Yahoo assetProfile / Wikidata / Wikipedia — source named per value); the registry-disclosed purpose follows. Disclosed segment/geographic revenue appears in the card above when the issuer reports it; official EDGAR-XBRL and ESEF facts feed the financials card since 2026-07-07. Nothing is estimated in the meantime.
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers products for oncology, hematology, immunology, cardiovascular, and neuroscience indications. SF
source: yahoo:assetProfile · retrieved 2026-07-18
Sector: Health Care peers
Registry-disclosed purpose: Access currently requires credentials — the Swiss registry (Zefix) API returned HTTP 401 anonymously (verified 2026-07-02); registered-purpose text will populate once free Zefix credentials are configured in .env.
Regulators of highest concern
Ranked by maximum applicability of evidence-backed matches; when none exist yet, the jurisdictional supervision context derived from listing venue/domicile is shown instead — labelled, never asserted as a match.
| Authority | Jur. | Matches | Max applicability | Max confidence |
|---|---|---|---|---|
| Health and Human Services Department | US | 7 | 0.70 | 0.78 |
| EU Publications Office (EU law) | EU | 1 | 0.70 | 0.78 |
Regulatory exposure — matches with evidence
The price-impact column is a LABELLED INFERENCE (EBI): reasoning about whether and why the exposure could bear on the share price, derived from the regulation's type, region and topic and the match layer/direction. It is not an asserted fact and states no magnitude; the Applicability/Confidence/Exposure figures and the linked evidence remain the sourced basis.
| Rule | Instrument | Relationship | Applicability | Confidence | Exposure | Potential price impact (inference) | Review |
|---|---|---|---|---|---|---|---|
| R-SECTOR-PHARMA_HEALTH | Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced | sector_topic_candidate_pharma_health | 0.70 | 0.78 | 0.69 | EBI Limited direct impact. An indirect topical (candidate) link to a US pharma / health measure: if it applied it could affect approval and compliance costs, or market access for regulated products, but any effect would be indirect and is unconfirmed. Inference from the match's regulation type, region and topic — not an asserted fact; no magnitude implied. | needs_review |
| R-SECTOR-PHARMA_HEALTH | Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for | sector_topic_candidate_pharma_health | 0.70 | 0.78 | 0.69 | EBI Limited direct impact. An indirect topical (candidate) link to a US pharma / health measure: if it applied it could affect approval and compliance costs, or market access for regulated products, but any effect would be indirect and is unconfirmed. Inference from the match's regulation type, region and topic — not an asserted fact; no magnitude implied. | needs_review |
| R-SECTOR-PHARMA_HEALTH | Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock Abs | sector_topic_candidate_pharma_health | 0.70 | 0.78 | 0.69 | EBI Limited direct impact. An indirect topical (candidate) link to a US pharma / health measure: if it applied it could affect approval and compliance costs, or market access for regulated products, but any effect would be indirect and is unconfirmed. Inference from the match's regulation type, region and topic — not an asserted fact; no magnitude implied. | needs_review |
| R-SECTOR-PHARMA_HEALTH | Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant S | sector_topic_candidate_pharma_health | 0.70 | 0.78 | 0.69 | EBI Limited direct impact. An indirect topical (candidate) link to a US pharma / health measure: if it applied it could affect approval and compliance costs, or market access for regulated products, but any effect would be indirect and is unconfirmed. Inference from the match's regulation type, region and topic — not an asserted fact; no magnitude implied. | needs_review |
| R-SECTOR-PHARMA_HEALTH | Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerv | sector_topic_candidate_pharma_health | 0.70 | 0.78 | 0.69 | EBI Limited direct impact. An indirect topical (candidate) link to a US pharma / health measure: if it applied it could affect approval and compliance costs, or market access for regulated products, but any effect would be indirect and is unconfirmed. Inference from the match's regulation type, region and topic — not an asserted fact; no magnitude implied. | needs_review |
| R-SECTOR-PHARMA_HEALTH | Medicare and State Health Care Programs: Fraud and Abuse; Request for Information Regardin | sector_topic_candidate_pharma_health | 0.70 | 0.78 | 0.69 | EBI Limited direct impact. An indirect topical (candidate) link to a US pharma / health measure: if it applied it could affect approval and compliance costs, or market access for regulated products, but any effect would be indirect and is unconfirmed. The measure is proposed / not yet in force, so any impact would be prospective and contingent on adoption. Inference from the match's regulation type, region and topic — not an asserted fact; no magnitude implied. | needs_review |
| R-SECTOR-PHARMA_HEALTH | CELEX:32026R1451: Commission Delegated Regulation (EU) 2026/1451 of 20 March 2026 amending | sector_topic_candidate_pharma_health | 0.70 | 0.78 | 0.00 | EBI Limited direct impact. An indirect topical (candidate) link to a EU pharma / health measure: if it applied it could affect approval and compliance costs, or market access for regulated products, but any effect would be indirect and is unconfirmed. Inference from the match's regulation type, region and topic — not an asserted fact; no magnitude implied. | needs_review |
| R-SECTOR-PHARMA_HEALTH | Recission of the National Cancer Institute Clinical Cancer Education Program Regulation | sector_topic_candidate_pharma_health | 0.70 | 0.78 | 0.69 | EBI Limited direct impact. An indirect topical (candidate) link to a US pharma / health measure: if it applied it could affect approval and compliance costs, or market access for regulated products, but any effect would be indirect and is unconfirmed. The measure is proposed / not yet in force, so any impact would be prospective and contingent on adoption. Inference from the match's regulation type, region and topic — not an asserted fact; no magnitude implied. | needs_review |
Recent filings — potential impact inputs
A filing flags potential impact only via evidence-backed matching between its disclosed content and tracked measures.
| Filed | Form | Title | Document |
|---|---|---|---|
| 2026-05-08 | 8-K | 8-K — BRISTOL MYERS SQUIBB CO | document |
| 2026-04-30 | 10-Q | 10-Q — BRISTOL MYERS SQUIBB CO | document |
| 2026-04-30 | 8-K | 8-K — BRISTOL MYERS SQUIBB CO | document |
| 2026-02-11 | 10-K | 10-K — BRISTOL MYERS SQUIBB CO | document |
| 2026-02-05 | 8-K | 8-K — BRISTOL MYERS SQUIBB CO | document |
| 2026-01-12 | 8-K | 8-K — BRISTOL MYERS SQUIBB CO | document |
| 2025-11-18 | 8-K | 8-K — BRISTOL MYERS SQUIBB CO | document |
| 2025-11-10 | 8-K | 8-K — BRISTOL MYERS SQUIBB CO | document |
| 2025-11-03 | 8-K | 8-K — BRISTOL MYERS SQUIBB CO | document |
| 2025-10-30 | 10-Q | 10-Q — BRISTOL MYERS SQUIBB CO | document |